Microbiome

An average person contains 30 trillion human cells, but even more microbes – about 39 trillion. In addition, there are possibly ten times that number of viral particles in the human virome. Understanding an individual’s microbiome is becoming increasingly important for diagnosing a broad range of diseases.

Patents that relate to the microbiome often need to be drafted differently from patents covering small molecule drugs or conventional diagnostics. For instance, some inventions lie in a way of affecting or detecting a heterogenous population of microbial cells. The cells could be defined in various ways, such as by their function or by their degree of genetic relatedness to a reference organism. Other inventions lie in a way of assessing the impact of the heterogenous population of microbes on drug metabolism, which might require functional definitions and/or specific assays to be written into the claims.

Applicants for microbiome-based patents need to be aware of legal obstacles in certain jurisdictions that would make certain claims very difficult to obtain. At Mewburn Ellis LLP, our world class training and broad experience makes us an excellent choice to be your creative, trusted advisors in this rapidly developing space.

To find out more, view our spotlight page here.

Open pages of EPO Opposition Trends in the Life Sciences Sector

Opposition Trends in the Life Sciences Sector

Special Report

In spring 2019, Mewburn Ellis undertook 350 hours of research, analysing more than 5,000 opposition cases filed at the European Patent Office over the last ten years, studying the timelines for hundreds of life sciences oppositions both before and after the EPO’s opposition streamlining initiative.

View the 2020 addendum for this report, based on information as it appeared on the EPO Register on 10 January 2021 and from bulk data sets extracted on this date.

Download the Report

Read our Blogs

Most Active Defendants in EPO Oppositions – 2024

Most Active Defendants in EPO Oppositions – 2024

by Katherine Green

Each year the European Patent Office (EPO) grants about 100,000 patents. Of these about 2-3% are opposed – meaning that a third party has formally filed a request that the EPO revoke the patent. This ...

Patent Strategies for Cell-based Therapeutics

Patent Strategies for Cell-based Therapeutics

by Nick Sutcliffe

Securing robust patent protection for cell-based therapeutics presents unique challenges, particularly before the European Patent Office (EPO). As the field of regenerative medicine and cell therapy ...

Mitochondria: the secret to regenerating human tissue?

Mitochondria: the secret to regenerating human tissue?

by Eliot Ward

Istesso co-founder Lisa Patel is researching how to regenerate and repair tissue by modulating mitochondria. The method has the potential to treat multiple diseases of ageing, such as arthritis, ...

Bispecific antibodies: A new way to combat drug resistance

Bispecific antibodies: A new way to combat drug resistance

by Tanis Keirstead

Biotech veteran Dr Rob Arathoon is pioneering a new way to counteract multi-drug resistance in cancer using bispecific antibodies. He explains his work.

Ozempic and the Anti-Ageing Opportunity

Ozempic and the Anti-Ageing Opportunity

by Katherine Collins

Semaglutide, a GLP-1 receptor agonist (GLP-1RA) best known by its brand names Ozempic and Wegovy, has already reshaped the treatment landscape for type 2 diabetes and obesity. However, compelling new ...

Are proprietors out of luck on appeal? It’s all in the reporting

Are proprietors out of luck on appeal? It’s all in the reporting

by Emily Garnett

The 2024 EPO Boards of Appeal Annual Report has recently been published, and, once again, it’s the appeal success statistics that are drawing the attention of patent applicants, proprietors, and ...

Learn More
Forward Magazines Overlapping 8

Mewburn Ellis

FORWARD MAGAZINE

Mewburn Ellis Forward is a biannual publication that celebrates the best of innovation and exploration. Through its pages we hope to inform and entertain, but also to encourage discussion about the most compelling developments taking place in the scientific and entrepreneurial world. Along the way, we’ll engage with the IP challenges that international organisations face every day.